Moderna, Thermo Fisher Scientific partner on COVID-19 manufacturing

By The Science Advisory Board staff writers

February 24, 2022 -- Moderna and Thermo Fisher Scientific have entered into a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.

Over the past several years, Thermo Fisher has been partnering with Moderna to support its development pipeline with both clinical research and contract manufacturing services. This included the quick scale-up of aseptic fill-finish services and packaging of its COVID-19 vaccine. As part of this expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services including lyophilized and liquid filling. In addition, the company will provide inspection, labeling and final packaging services.

Moderna is a biotechnology company pioneering mRNA therapeutics and vaccines. Thermo Fisher Scientific is renowned for serving science.

No financial details were disclosed.

Moderna, Carisma collaborate to develop CAR M for oncology
Moderna and Carisma Therapeutics have entered into a strategic collaboration agreement to discover, develop, and commercialize in vivo engineered CAR...
Moderna launches AI academy with Carnegie Mellon University
Moderna has launched the Artificial Intelligence (AI) Academy for its employees in partnership with Carnegie Mellon University. The AI Academy is intended...
Moderna plans to bring mRNA manufacturing to Canada
Moderna has signed a memorandum of understanding with the government of Canada to build a mRNA vaccine manufacturing facility in Canada.
Autolus, Moderna ink license agreement
Biopharmaceutical company Autolus Therapeutics has granted Moderna exclusive license to develop and market mRNA therapeutics that include Autolus' binding...
EMA takes positive stance on Moderna COVID-19 vaccine for adolescents
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has taken a positive position on marketing authorization for Moderna's...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter